HLA-C and synovial sarcoma: Despite challenges posed by the loss of major histocompatibility complex (MHC) expression, strategies to enhance MHC levels and neoantigen recognition remain promising; for instance, NY-ESO-1-specific TCR-T cells demonstrated significant clinical efficacy in synovial sarcoma [172].